Relapses of Plasmodium vivax infection usually result from activation of heterologous hypnozoites.
about
Understanding the population genetics of Plasmodium vivax is essential for malaria control and eliminationDeterminants of relapse periodicity in Plasmodium vivax malariaNeutral polymorphisms in putative housekeeping genes and tandem repeats unravels the population genetics and evolutionary history of Plasmodium vivax in IndiaThe potential elimination of Plasmodium vivax malaria by relapse treatment: insights from a transmission model and surveillance data from NW IndiaComparative genomics of the neglected human malaria parasite Plasmodium vivaxPrimaquine for preventing relapse in people with Plasmodium vivax malaria treated with chloroquineArtemisinin-based combination therapy for treating uncomplicated Plasmodium vivax malariaArtemisinin-based combination therapy for treating uncomplicated Plasmodium vivax malariaArtemisinin-based combination therapy for the treatment of uncomplicated Plasmodium vivax malaria and the prevention of relapsesArtemisinin combination therapy for vivax malariaTafenoquine and its potential in the treatment and relapse prevention of Plasmodium vivax malaria: the evidence to dateA review of mixed malaria species infections in anopheline mosquitoesPrimaquine in vivax malaria: an update and review on management issuesThe anaemia of Plasmodium vivax malariaPrimaquine radical cure of Plasmodium vivax: a critical review of the literatureTargeting vivax malaria in the Asia Pacific: The Asia Pacific Malaria Elimination Network Vivax Working GroupVisualisation and quantitative analysis of the rodent malaria liver stage by real time imagingPlasmodium vivax Landscape in Brazil: Scenario and ChallengesEstablishment of an in vitro assay for assessing the effects of drugs on the liver stages of Plasmodium vivax malariaThe use of artemether-lumefantrine for the treatment of uncomplicated Plasmodium vivax malariaEfficacy and safety of dihydroartemisinin-piperaquine for treatment of Plasmodium vivax malaria in endemic countries: meta-analysis of randomized controlled studiesA high resolution case study of a patient with recurrent Plasmodium vivax infections shows that relapses were caused by meiotic siblings.Modeling the dynamics of Plasmodium vivax infection and hypnozoite reactivation in vivoThe Plasmodium vivax merozoite surface protein 3β sequence reveals contrasting parasite populations in southern and northwestern ThailandPlasmodium vivax Diversity and Population Structure across Four ContinentsVariation in Human Cytochrome P-450 Drug-Metabolism Genes: A Gateway to the Understanding of Plasmodium vivax RelapsesSafety, efficacy and pharmacokinetic evaluations of a new coated chloroquine tablet in a single-arm open-label non-comparative trial in Brazil: a step towards a user-friendly malaria vivax treatmentGenome-Scale Protein Microarray Comparison of Human Antibody Responses in Plasmodium vivax Relapse and ReinfectionGlobal Epidemiology of Plasmodium vivaxReactive Case Detection for Plasmodium vivax Malaria Elimination in Rural Amazonia.VivaxGEN: An open access platform for comparative analysis of short tandem repeat genotyping data in Plasmodium vivax populationsDeterminants of in vitro drug susceptibility testing of Plasmodium vivax.A randomised trial of an eight-week, once weekly primaquine regimen to prevent relapse of plasmodium vivax in Northwest Frontier Province, PakistanAmplification of pvmdr1 associated with multidrug-resistant Plasmodium vivaxama1 genes of sympatric Plasmodium vivax and P. falciparum from Venezuela differ significantly in genetic diversity and recombination frequency.A simple scoring system to differentiate between relapse and re-infection in patients with recurrent melioidosisRevisiting the design of phase III clinical trials of antimalarial drugs for uncomplicated Plasmodium falciparum malaria.In vivo and in vitro efficacy of amodiaquine monotherapy for treatment of infection by chloroquine-resistant Plasmodium vivax.Plasmodium cynomolgi infections in rhesus macaques display clinical and parasitological features pertinent to modelling vivax malaria pathology and relapse infectionsResistance to therapies for infection by Plasmodium vivax
P2860
Q17485678-8BC61AC7-DFEA-40E5-A06E-84D648F86427Q17485692-55C57F38-E49E-4B18-B4E0-91F0623F1879Q21562240-7C1ECD14-C51D-4AE3-9DD0-8A1E048A9618Q21562247-81F97D7D-36B7-474D-A47C-6A66BA74E360Q22122202-AADD2434-A897-4EE1-B46B-7951A6ACB7AFQ24202900-6C5F86CF-551E-41E7-BDD7-D6FBA8274D44Q24202910-3C9651E2-E5D7-4C22-9897-38BAFB091AAEQ24235351-17BFF1C7-0A64-449D-B45B-2D8B64A16B20Q24236067-55B55769-5F8E-41E2-B816-6A2C23A2A921Q24622539-430B9905-E621-4C8D-9039-600C6A0956F6Q26741307-0EE3D436-0FDC-4EB9-87A1-70BA5CC4E60EQ26862739-901770D5-01F0-4502-A5E6-392A4711C004Q27003856-5E1DEAD4-8690-4583-AE3B-58FB77F603BBQ27026970-CDE0D1BC-4E63-47F9-8662-25155AF39BD9Q27027939-4E925072-17D0-4D7E-B532-8BCF409C01CFQ27304660-20B32520-6EEB-48F1-B6A5-9A88EE6F7266Q27335248-A510DD2C-C0FC-4608-B7D7-A3E41FF0E0B4Q28353930-C3002CD9-38F5-4FE7-919E-F4EDBEA70931Q28476463-99C628B5-C5A7-44B7-8C60-AC922B60B066Q28478579-0993F378-E703-42FA-A23E-93DFD7B724C2Q28535686-84BA0F55-06E7-4E29-9F14-CC7C89C3D0D5Q28539392-74AC0742-137C-4818-8E45-90BDA6D43AF6Q28544459-0203F7BA-7003-4CF2-9633-30867991AF93Q28545082-EE23E381-0F63-4D93-8022-B3CCF13FC186Q28545982-91C473FA-B559-4D31-9764-3305394D3B18Q28553162-221C38EF-CDFE-486E-BDA7-F21351947C25Q28595615-DA078F75-6672-4E21-8CAE-E5B820A7E97CQ28606685-D4E86F61-31C9-46D7-B19A-3CB911A7C569Q30249044-67AE3B28-8DB6-4A16-BEB6-A90A7E02D1E0Q30379318-8D164A93-641F-4C85-A3D8-48A6EC266FACQ30491283-2D261584-73BE-4627-A0B8-76299FE5142EQ33313565-C8112AD2-44EF-4E30-BED5-4F49574227E1Q33358051-CF00578C-A820-4241-B6FF-4DD53D41006CQ33371043-29E9FA07-E5C9-4C98-B4CE-11D2A9ED88E1Q33375053-22FB262D-01ED-43D8-ACF0-9C60D6DB5FF4Q33380206-B4F8F3E1-088E-4C0B-864C-ECE6DDDD3A2AQ33385477-FA171FBE-ADDA-4C8F-B6A8-C2CCD53F88A0Q33395221-919C8588-98A1-42B4-B23C-A5FD704ECBC2Q33435123-8D45ECC1-7260-4CB4-91C3-EDE4BE57E06FQ33481576-474FFB1F-DB6F-4C4B-8335-6EB51FDB5D8D
P2860
Relapses of Plasmodium vivax infection usually result from activation of heterologous hypnozoites.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
2007年论文
@zh
2007年论文
@zh-cn
name
Relapses of Plasmodium vivax i ...... n of heterologous hypnozoites.
@en
Relapses of Plasmodium vivax i ...... n of heterologous hypnozoites.
@nl
type
label
Relapses of Plasmodium vivax i ...... n of heterologous hypnozoites.
@en
Relapses of Plasmodium vivax i ...... n of heterologous hypnozoites.
@nl
prefLabel
Relapses of Plasmodium vivax i ...... n of heterologous hypnozoites.
@en
Relapses of Plasmodium vivax i ...... n of heterologous hypnozoites.
@nl
P2093
P50
P356
P1476
Relapses of Plasmodium vivax i ...... n of heterologous hypnozoites.
@en
P2093
Amitab Nandy
Daniel Sudimack
Jane Carlton
Jean-Paul Guthmann
Jung Ryong Kim
Naowarat Tanomsing
Timothy J C Anderson
P304
P356
10.1086/512241
P407
P50
P577
2007-02-26T00:00:00Z